search
Back to results

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

Primary Purpose

Colitis, Ulcerative

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Spesolimab IV infusion
Spesolimab SC solution for injection
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colitis, Ulcerative

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients, aged ≥18 years
  • Signed and dated written informed consent for 1368.17, in accordance with GCP and local legislation prior to admission into the trial
  • Women of childbearing potential (WOCBP) must be ready to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. Note: A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tuba ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
  • Have completed treatment and the EOT visit in the previous trial and are willing and able to continue treatment in 1368.17.

Exclusion Criteria:

  • Have experienced study treatment-limiting adverse events during induction treatment with study drug
  • Have developed any of the exclusion criteria from the original induction study with the following exceptions:

    • Cases of disease limited to the rectum extending <15 cm past the anal verge are allowed to be included in study 1368.17
    • Cases of latent TB. Patients with newly emerging latent TB during preceding study are allowed to be included in study 1368.17, provided they receive appropriate treatment according to local guidelines

Sites / Locations

  • Medical Research Center of Connecticut, LLC
  • Emory University
  • University of Chicago
  • Columbia University Medical Center-New York Presbyterian Hospital
  • Digestive Disease Specialists Inc
  • Southern Star Research Institute, LLC
  • Texas Digestive Disease Consultants - Southlake
  • Hunter Holmes McGuire VA Medical Center
  • Ordensklinikum Linz GmbH - Barmherzige Schwestern
  • AKH - Medical University of Vienna
  • UZ Leuven
  • Centre Hospitalier Universitaire de Liège
  • Victoria Hospital (LHSC)
  • Universitätsklinikum Erlangen
  • Klinikum Esslingen GmbH
  • Asklepios Kliniken Westklinikum Hamburg
  • Medizinische Hochschule Hannover
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel
  • Universitätsklinikum Ulm
  • Azienda Ospedaliera Universitaria di Padova
  • Istituto Clinico Humanitas
  • Sapporo Tokushukai Hospital
  • Sapporo Higashi Tokushukai Hospital
  • Hyogo College of Medicine Hospital
  • Ofuna Chuo Hospital
  • Tokyo Medical and Dental University Hospital
  • Tokyo Yamate Medical Center
  • Inje University Haeundae Paik Hospital
  • Yeungnam University Medical Center
  • National Medical Institute MSWiA
  • FSB Instit. HC Irkutsk Scient.Cent. Sibirian Branch of Russ. Acad. Scien.
  • Federal State Budgetary Institution " State Scientific Center of Coloproctology" MOH Russia
  • Military Medical Academy n.a. C. M. Kirov, St. Petersburg
  • Hospital Virgen del Rocío
  • Hospital Politècnic La Fe
  • Doncaster Royal Infirmary
  • Guy's Hospital
  • Whiston Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

All Patients

Arm Description

1 arm solution for injection Spesolimab will be used for all patients. Those who did not respond to previous induction treatment or experienced disease flare will need i.v. re-induction treatment also

Outcomes

Primary Outcome Measures

The exposure adjusted rate of patients reporting a treatment emergent adverse event (TEAE)

Secondary Outcome Measures

Proportion of patients with clinical remission

Full Information

First Posted
August 24, 2018
Last Updated
May 15, 2023
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT03648541
Brief Title
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
Official Title
An Open Label, Long Term Safety Trial of BI 655130 (SPESOLIMAB) Treatment in Patients With Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
October 29, 2018 (Actual)
Primary Completion Date
May 3, 2023 (Actual)
Study Completion Date
May 3, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the long-term safety of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials To evaluate the long-term efficacy of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colitis, Ulcerative

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
79 (Actual)

8. Arms, Groups, and Interventions

Arm Title
All Patients
Arm Type
Experimental
Arm Description
1 arm solution for injection Spesolimab will be used for all patients. Those who did not respond to previous induction treatment or experienced disease flare will need i.v. re-induction treatment also
Intervention Type
Drug
Intervention Name(s)
Spesolimab IV infusion
Intervention Description
Solution for infusion
Intervention Type
Drug
Intervention Name(s)
Spesolimab SC solution for injection
Intervention Description
Solution for injection
Primary Outcome Measure Information:
Title
The exposure adjusted rate of patients reporting a treatment emergent adverse event (TEAE)
Time Frame
Up to week 336
Secondary Outcome Measure Information:
Title
Proportion of patients with clinical remission
Time Frame
Up to 336 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients, aged ≥18 years Signed and dated written informed consent for 1368.17, in accordance with GCP and local legislation prior to admission into the trial Women of childbearing potential (WOCBP) must be ready to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. Note: A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tuba ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Have completed treatment and the EOT visit in the previous trial and are willing and able to continue treatment in 1368.17. Exclusion Criteria: Have experienced study treatment-limiting adverse events during induction treatment with study drug Have developed any of the exclusion criteria from the original induction study with the following exceptions: Cases of disease limited to the rectum extending <15 cm past the anal verge are allowed to be included in study 1368.17 Cases of latent TB. Patients with newly emerging latent TB during preceding study are allowed to be included in study 1368.17, provided they receive appropriate treatment according to local guidelines
Facility Information:
Facility Name
Medical Research Center of Connecticut, LLC
City
Hamden
State/Province
Connecticut
ZIP/Postal Code
06518
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Columbia University Medical Center-New York Presbyterian Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Digestive Disease Specialists Inc
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73112
Country
United States
Facility Name
Southern Star Research Institute, LLC
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Texas Digestive Disease Consultants - Southlake
City
Southlake
State/Province
Texas
ZIP/Postal Code
76092
Country
United States
Facility Name
Hunter Holmes McGuire VA Medical Center
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23249
Country
United States
Facility Name
Ordensklinikum Linz GmbH - Barmherzige Schwestern
City
Linz
ZIP/Postal Code
4010
Country
Austria
Facility Name
AKH - Medical University of Vienna
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Centre Hospitalier Universitaire de Liège
City
Liège
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Victoria Hospital (LHSC)
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5W9
Country
Canada
Facility Name
Universitätsklinikum Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Klinikum Esslingen GmbH
City
Esslingen
ZIP/Postal Code
73730
Country
Germany
Facility Name
Asklepios Kliniken Westklinikum Hamburg
City
Hamburg
ZIP/Postal Code
22559
Country
Germany
Facility Name
Medizinische Hochschule Hannover
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Universitätsklinikum Schleswig-Holstein, Campus Kiel
City
Kiel
ZIP/Postal Code
24105
Country
Germany
Facility Name
Universitätsklinikum Ulm
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
Azienda Ospedaliera Universitaria di Padova
City
Padova
ZIP/Postal Code
35128
Country
Italy
Facility Name
Istituto Clinico Humanitas
City
Rozzano (MI)
ZIP/Postal Code
20089
Country
Italy
Facility Name
Sapporo Tokushukai Hospital
City
Hokkaido, Sapporo
ZIP/Postal Code
004-0041
Country
Japan
Facility Name
Sapporo Higashi Tokushukai Hospital
City
Hokkaido, Sapporo
ZIP/Postal Code
065-0033
Country
Japan
Facility Name
Hyogo College of Medicine Hospital
City
Hyogo, Nishinomiya
ZIP/Postal Code
663-8501
Country
Japan
Facility Name
Ofuna Chuo Hospital
City
Kanagawa, Kamakura
ZIP/Postal Code
247-0056
Country
Japan
Facility Name
Tokyo Medical and Dental University Hospital
City
Tokyo, Bunkyo-ku
ZIP/Postal Code
113-8519
Country
Japan
Facility Name
Tokyo Yamate Medical Center
City
Tokyo, Shinjuku
ZIP/Postal Code
169-0073
Country
Japan
Facility Name
Inje University Haeundae Paik Hospital
City
Busan
ZIP/Postal Code
48108
Country
Korea, Republic of
Facility Name
Yeungnam University Medical Center
City
Daegu
ZIP/Postal Code
42415
Country
Korea, Republic of
Facility Name
National Medical Institute MSWiA
City
Warsaw
ZIP/Postal Code
02-507
Country
Poland
Facility Name
FSB Instit. HC Irkutsk Scient.Cent. Sibirian Branch of Russ. Acad. Scien.
City
Irkutsk
ZIP/Postal Code
664033
Country
Russian Federation
Facility Name
Federal State Budgetary Institution " State Scientific Center of Coloproctology" MOH Russia
City
Moscow
ZIP/Postal Code
123423
Country
Russian Federation
Facility Name
Military Medical Academy n.a. C. M. Kirov, St. Petersburg
City
St. Petersburg
ZIP/Postal Code
194044
Country
Russian Federation
Facility Name
Hospital Virgen del Rocío
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Hospital Politècnic La Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Doncaster Royal Infirmary
City
Doncaster
ZIP/Postal Code
DN2 5LT
Country
United Kingdom
Facility Name
Guy's Hospital
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
Whiston Hospital
City
Prescot
ZIP/Postal Code
L35 5DR
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
IPD Sharing Time Frame
After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD Sharing Access Criteria
For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
IPD Sharing URL
https://www.mystudywindow.com/msw/datasharing
Links:
URL
https://www.mystudywindow.com
Description
Related Info

Learn more about this trial

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

We'll reach out to this number within 24 hrs